Eli Lilly expects to launch diabetes drug Mounjaro in India next year: CEO
Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions.;
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-29 07:00 GMT | Update On 2024-03-21 09:51 GMT
Advertisement
Hyderabad: U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday.
The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are testing their own versions of weight-loss drugs, while illegal versions are also sold online.
"Our famous Mounjaro – it's under review now. So, perhaps as early as next year to the Indian market," Ricks told Reuters on the sidelines of the BioAsia conference in the southern state of Telangana.
When asked about potentially partnering with others to bring the drug to the market, Ricks said the U.S. drugmaker was "open to any way to reach more patients as long as it makes sense for the company and we can supply the market."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.